ATE178211T1 - Zusammensetzung zur behandlung von tumoren mit hoher tyrosinase aktivität - Google Patents

Zusammensetzung zur behandlung von tumoren mit hoher tyrosinase aktivität

Info

Publication number
ATE178211T1
ATE178211T1 AT92924270T AT92924270T ATE178211T1 AT E178211 T1 ATE178211 T1 AT E178211T1 AT 92924270 T AT92924270 T AT 92924270T AT 92924270 T AT92924270 T AT 92924270T AT E178211 T1 ATE178211 T1 AT E178211T1
Authority
AT
Austria
Prior art keywords
treatment
tyrosinase
tyrosinase activity
tumors
composition
Prior art date
Application number
AT92924270T
Other languages
English (en)
Inventor
David Rubin
Original Assignee
David Rubin
Schwimmer Adolph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Rubin, Schwimmer Adolph filed Critical David Rubin
Application granted granted Critical
Publication of ATE178211T1 publication Critical patent/ATE178211T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
AT92924270T 1991-11-04 1992-11-04 Zusammensetzung zur behandlung von tumoren mit hoher tyrosinase aktivität ATE178211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78734791A 1991-11-04 1991-11-04

Publications (1)

Publication Number Publication Date
ATE178211T1 true ATE178211T1 (de) 1999-04-15

Family

ID=25141186

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924270T ATE178211T1 (de) 1991-11-04 1992-11-04 Zusammensetzung zur behandlung von tumoren mit hoher tyrosinase aktivität

Country Status (11)

Country Link
US (1) US5340803A (de)
EP (1) EP0619704B1 (de)
AT (1) ATE178211T1 (de)
AU (1) AU665220B2 (de)
CA (1) CA2122922C (de)
DE (1) DE69228829T2 (de)
DK (1) DK0619704T3 (de)
ES (1) ES2132137T3 (de)
GR (1) GR3030259T3 (de)
MX (1) MX9206309A (de)
WO (1) WO1993008688A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476842A (en) * 1991-11-04 1995-12-19 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US5760008A (en) * 1991-11-04 1998-06-02 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting metastases of malignant tumors
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US5543146A (en) * 1995-01-20 1996-08-06 Prostahelp, Inc. Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland
CA2337690C (en) * 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US7927612B2 (en) * 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
WO2002087530A1 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation Tyrosinase assay
CN1649600A (zh) 2002-02-28 2005-08-03 A&D生物科学公司 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
EP1993613A2 (de) * 2006-03-15 2008-11-26 Mallinckrodt, Inc. Chelatkonjugate mit einem substituierten aromatischen anteil und derivate davon
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
WO2016086070A1 (en) 2014-11-26 2016-06-02 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
WO2016196614A1 (en) * 2015-06-01 2016-12-08 University Of Kentucky Research Foundation Chloroquine induction of par-4 and treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212014A1 (de) * 1971-04-21 1972-10-26 Deutsche Akademie der Wissenschaf ten zu Berlin, χ 1199 Berlin Verfahren zur fermentativen Spaltung von Transportformen von Chemotherapeutika, insbesondere Cancerostatica
US4424348A (en) * 1978-10-13 1984-01-03 Adolf W. Schwimmer Methods of manufacture of nitrile-containing glucuronic acid conjugates
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4481195A (en) * 1978-10-13 1984-11-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma

Also Published As

Publication number Publication date
EP0619704B1 (de) 1999-03-31
WO1993008688A1 (en) 1993-05-13
AU665220B2 (en) 1995-12-21
US5340803A (en) 1994-08-23
CA2122922C (en) 2004-03-30
DE69228829D1 (de) 1999-05-06
MX9206309A (es) 1994-05-31
ES2132137T3 (es) 1999-08-16
CA2122922A1 (en) 1993-05-13
GR3030259T3 (en) 1999-08-31
DK0619704T3 (da) 1999-10-11
DE69228829T2 (de) 1999-10-21
EP0619704A4 (en) 1997-03-26
EP0619704A1 (de) 1994-10-19
AU3064192A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
ATE178211T1 (de) Zusammensetzung zur behandlung von tumoren mit hoher tyrosinase aktivität
DE69839586D1 (de) Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
GEP20043322B (en) C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
GEP20032922B (en) Benzoheterocycles and Their Use as MEK Inhibitors
PL351280A1 (en) Methods and compositions for treating solid tumors
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE69006684D1 (de) Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
AR003430A1 (es) Una composicion farmaceutica para inhibir el crecimiento de canceres
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
DE59911734D1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
GEP20043231B (en) Resorcinol Composition
GEP20043239B (en) C10 Carbonate Substituted Taxanes as Antitumor Agents
BG105862A (en) Light, extruded compositions containing a light, extrudable, ceramic carrier, methods for their use and preparartion
AU3618695A (en) Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases
DE69629282D1 (de) Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
GEP20043226B (en) C7 Carbonate Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof as Agents to Inhibit Tumor Growth
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb
AR034398A1 (es) Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee